NCT03732846Unknown2 期
One-arm, Phase II, Single-center Clinical Study of Anlotinib in the Treatment of Recurrent Small Cell Lung Cancer
Peking University Cancer Hospital & Institute1 个研究点 分布在 1 个国家目标入组 43 人开始时间: 2018年11月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 43
- 试验地点
- 1
- 主要终点
- PFS (Progression-Free survival)
研究概览
简要总结
Exploring the efficacy and safety of Anlotinib in patients with relapsed small cell lung cancer
详细描述
This is an one-arm, phase II, single-center clinical study of Anlotinib in the treatment of recurrent small cell lung cancer, the objection is to exploring the efficacy and safety of Anlotinib in patients with relapsed small cell lung cancer.It is going to enroll 43 patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years old;
- •Histological or cytologically confirmed small cell lung cancer;
- •Systemic chemotherapy that has previously received at least two or more lines regimen, followed by disease progression or recurrence;
- •According to the RECIST 1.1 standard, there is at least one measurable target lesion;
- •ECOG physical score 0-1 points; expected survival time ≥ 3 months;
- •The main organ function meets the following criteria:
- •blood routine: absolute value of neutrophils ≥ 1.5 × 109 / L, platelets ≥ 75 × 109 / L, hemoglobin ≥ 80 g / L;
- •Blood biochemistry: total bilirubin ≤ 1.5 times the upper limit of normal value, aspartate aminotransferase and alanine aminotransferase ≤ 2.5 times the upper limit of normal value (if liver metastasis, ≤ upper limit of normal value 5 times), serum creatinine ≤ 1.5 times the upper limit of normal;
- •Subjects voluntarily joined the study and signed informed consent, with good adherence and follow-up.
排除标准
- •Subjects who have previously used Anlotinib;
- •Systematic anti-tumor treatments have been performed for the past 2 weeks, including chemotherapy, radiotherapy (except for metastatic lesions other than thoracic radiation), targeted therapy, immunotherapy, and biotherapy;
- •Imaging (CT or MRI) shows central tumors in which tumor lesions invade local large blood vessels; imaging (CT or MRI) shows significant pulmonary cavitary or necrotizing tumors; or other factors identified by the investigator that may cause hemoptysis disease;
- •A history of active bleeding within the first 6 months of screening, or receiving thrombolysis or anticoagulant therapy, or the investigator believes that there is a clear tendency to gastrointestinal bleeding (such as esophageal varices with bleeding risk, local activity) Ulcer lesions, etc.) or active hemoptysis;
- •A thrombotic event occurs within 6 months (including arteriovenous thrombosis, pulmonary embolism, cerebrovascular accident, including transient ischemic attack, etc.);
- •Cardiac diseases with obvious clinical symptoms, such as: congestive heart failure, coronary heart disease with obvious symptoms, arrhythmia with difficult drug control (including clinically significant QTc interval prolongation history, or screening period QTc interval women >470ms, Male > 450ms), had myocardial infarction within 6 months, or cardiac insufficiency;
- •Hypertension, which is uncontrolled by the drug, is defined as: systolic blood pressure ≥ 160 mmHg, or diastolic blood pressure ≥ 100 mmHg;
- •Clinically obvious gastrointestinal abnormalities, which may affect the intake, transport or absorption of drugs (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.), or patients with total gastrectomy;
- •Surgery (<28 days) before the study was selected or the surgical incision did not completely heal, or there were other unhealed wounds;
- •Active or uncontrolled serious infections;
- •Pregnant or lactating women; those who have fertility are unwilling or unable to take effective contraceptive measures;
- •Increasing the risk associated with participating in a study or study drug, and at the discretion of the investigator, may lead to other conditions in which the patient is not eligible for inclusion in the study.
研究组 & 干预措施
Anlotinib
Experimental
Take Anlotinib 12mg once daily for two weeks, stop for one week, the program repeats every 21 days until it can not tolerate, or disease progression.
干预措施: Anlotinib (Drug)
结局指标
主要结局
PFS (Progression-Free survival)
时间窗: From the date Into this study (signed ICF) to tumor progression or death for any reason, up to 18 months.
From the date Into this study (signed ICF) to tumor progression or death for any reason.
次要结局
- OS (Overall survival)(From the date Into this study (signed ICF) to death for any reason, up to 18months.)
- DCR (Disease control rate)(From the beginning of treatment, CT and ultrasound examinations are performed every six weeks to assess changes in the disease until the disease progression or death, up to 18 months.)
- ORR (Objective control rate)(From the beginning of treatment, CT and ultrasound examinations are performed every six weeks to assess changes in the disease until the disease progression or death, up to 18 months.)
研究者
Jian Fang
professor
Peking University Cancer Hospital & Institute
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung CancerExtensive-stage Small Cell Lung CancerNCT03841136Fudan University70
尚未招募
2 期
Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell CarcinomaRenal Cell CarcinomaNCT05124431Fudan University30
已完成
2 期
Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)Small Cell Lung CancerNCT03059797Chia Tai Tianqing Pharmaceutical Group Co., Ltd.120
Unknown
2 期
Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)Non-small Cell Lung CancerNCT02006043Li Zhang54
Unknown
2 期
The Efficacy and Safety of Apatinib Monotherapy in Maintenance Treatment of Extensive-stage Small-cell Lung CancerApatinib in Maintenance TreatmentNCT03129698Junling Li52